Combination therapy continues to evolve in the renal-cell carcinoma space. However, along with improved efficacy come the tests of adverse events and their impact on quality of life. Please join Laura Wood, RN, MSN, OCN, Virginia Seery, MSN, RN, ANP-BC, AOCNP, and Megan Price, MSN, APRN, FNP-C, as they discuss the ways in which drug combinations improve outcomes but also present their own set of challenges for patients’ quality of life.
Video Library —June 21, 2021
Categories:
Interview with the InnovatorsBaylor Charles A. Sammons Cancer Center
Dallas, TX
Dallas, TX
Beth Israel Deaconess Medical Center, Harvard Medical School Teaching Hospital, Boston, MA
Cleveland Clinic Taussig Cancer Center
Cleveland, OH
Cleveland, OH
Last modified: August 10, 2023